- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Ochsner Receives an 'A' for Patient Safety in Leapfrog Hospital Safety Grade
The Ochsner Health System facilities, including 3 partner hospitals, have received an A grade from the Leapfrog Group’s Hospital Safety Grade.
The Ochsner Health System facilities, including 3 partner hospitals, have received an 'A' grade from the Leapfrog Group’s Hospital Safety Grade. The designation awards efforts for protecting patients from harm and meeting the highest safety standards in the country.
“To be recognized nationally as an ‘A’ hospital is an accomplishment the whole community should take pride in,” said Leah Binder, president and chief executive officer of The Leapfrog Group. “Hospitals that earn an ‘A’ grade are making it a priority to protect patients from preventable medical harm and error. We congratulate hospital leaders, board members, staff, volunteers and clinicians who work so hard to earn this A.”
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
What We’re Reading: New HPV Screenings; Lung Cancer Pills; Migraine Relief Device
November 9th 2023A study suggests that human papillomavirus (HPV) screenings should be updated due to effective HPV vaccines; a new study shows that osimertinib (Tagrisso, AstraZeneca) reduced both the 5-year risk of recurrent cancer and the risk of death in patients with stage 1B to 3A lung cancer; a new smartphone-controlled technology could help those who suffer from migraines.
Read More
